Wells Fargo & Company Galera Therapeutics, Inc. Transaction History

Wells Fargo & Company

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.14 - $0.27 $11 - $21	80 Added 6.1%	1,391 $0
Q4 2023 Feb 09, 2024	SELL	$0.09 - $0.27 $357 - $1,073	-3,977 Reduced 75.21%	1,311 $0
Q3 2023 Nov 13, 2023	BUY	$0.17 - $3.0 $516 - $9,114	3,038 Added 135.02%	5,288 $0
Q2 2023 Aug 15, 2023	BUY	$2.5 - $3.42 $270 - $369	108 Added 5.04%	2,250 $7,000
Q1 2023 May 12, 2023	BUY	$1.48 - $2.68 $2 - $5	2 Added 0.09%	2,142 $5,000
Q4 2022 Feb 13, 2023	BUY	$1.34 - $1.78 $16 - $21	12 Added 0.56%	2,140 $3,000
Q3 2022 Nov 14, 2022	BUY	$1.15 - $2.1 $74 - $136	65 Added 3.15%	2,128 $3,000
Q2 2022 Aug 12, 2022	BUY	$1.24 - $2.39 $7 - $14	6 Added 0.29%	2,063 $3,000
Q4 2021 Feb 14, 2022	SELL	$1.27 - $8.28 $1,520 - $9,911	-1,197 Reduced 36.79%	2,057 $9,000
Q3 2021 Nov 15, 2021	SELL	$7.04 - $10.49 $21 - $31	-3 Reduced 0.09%	3,254 $26,000
Q2 2021 Aug 16, 2021	SELL	$6.08 - $10.44 $83,630 - $143,602	-13,755 Reduced 80.85%	3,257 $32,000
Q1 2021 May 13, 2021	SELL	$8.35 - $12.39 $146,951 - $218,051	-17,599 Reduced 50.85%	17,012 $150,000
Q4 2020 Feb 09, 2021	BUY	$8.02 - $12.81 $222,923 - $356,066	27,796 Added 407.87%	34,611 $354,000
Q3 2020 Nov 05, 2020	SELL	$6.96 - $9.12 $65,444 - $85,755	-9,403 Reduced 57.98%	6,815 $62,000
Q2 2020 Aug 13, 2020	BUY	$7.14 - $14.41 $78,061 - $157,544	10,933 Added 206.87%	16,218 $116,000
Q1 2020 May 14, 2020	BUY	$5.89 - $17.67 $31,128 - $93,385	5,285 New	5,285 $50,000

909K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $1.07M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.